TDUP:NASDAQThredUp Inc. Analysis
Data as of 2026-06-16 - not real-time
$5.21
Latest Price
8/10Risk
Risk Level: High
Executive Summary
ThredUp reported Q1 2026 revenue of $81.7 million, a 14.6% year‑over‑year increase that topped expectations. The company maintained a gross margin of 79.4%, but its operating margin slipped to ‑8.1%, keeping profitability in the red with a trailing EPS of ‑0.19. The stock opened at $5.17 and is trading at $5.21, sitting just below the identified resistance level of $5.41 and well above the support of $3.87. Technical indicators show a bullish MACD crossover (line 0.193 vs signal 0.148) and an RSI of 68, indicating near‑overbought conditions. Volume is on an increasing trend, reinforcing the short‑term momentum sparked by the earnings surprise.
However, a discounted cash‑flow model values the shares at $1.49, implying a 54% upside/downside gap and suggesting the market is overvalued relative to fundamentals. The stock’s beta of 2.2 and 30‑day volatility of 63% expose it to amplified market swings, while a max drawdown of ‑74% highlights historical downside risk. The balance sheet shows $49.5 M cash versus $52.2 M debt, yielding a debt‑to‑equity of 88%, which adds financial strain. Despite a strong‑buy consensus from five analysts, the combination of negative earnings, high valuation multiples (P/B ≈ 11) and sector sensitivity to discretionary spending tempers enthusiasm. Consequently, investors should view the current price as a short‑term rally opportunity but remain cautious about holding the position beyond the next few quarters.
However, a discounted cash‑flow model values the shares at $1.49, implying a 54% upside/downside gap and suggesting the market is overvalued relative to fundamentals. The stock’s beta of 2.2 and 30‑day volatility of 63% expose it to amplified market swings, while a max drawdown of ‑74% highlights historical downside risk. The balance sheet shows $49.5 M cash versus $52.2 M debt, yielding a debt‑to‑equity of 88%, which adds financial strain. Despite a strong‑buy consensus from five analysts, the combination of negative earnings, high valuation multiples (P/B ≈ 11) and sector sensitivity to discretionary spending tempers enthusiasm. Consequently, investors should view the current price as a short‑term rally opportunity but remain cautious about holding the position beyond the next few quarters.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish MACD and rising volume
- Revenue beat and raised outlook
- Proximity to resistance level
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained revenue growth versus negative profitability
- High valuation gap to DCF fair value
- Elevated beta and volatility
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Overvaluation relative to fundamentals
- Persistent operating losses and high debt load
- Sector sensitivity and market risk
Key Metrics & Analysis
Financial Health
Revenue Growth14.60%
Profit Margin-6.69%
P/E Ratio-86.8
ROE-37.19%
ROA-7.91%
Debt/Equity87.87
P/B Ratio11.2
Op. Cash Flow$9.7M
Free Cash Flow$8.1M
Technical Analysis
TrendNeutral
RSI68.3
Support$3.87
Resistance$5.41
MA 20$4.64
MA 50$4.41
MA 200$6.34
MACDBullish
VolumeIncreasing
Fear & Greed Index92.5
Valuation
Fair Value$1.49
Target Price$8.04
Upside/Downside54.32%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.21
Volatility62.97%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.